Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ocular Hypertension Eye Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Louisville, Kentucky, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes
Patient requires IOP-lowering drug in both eyes

Exclusion criteria

Uncontrolled medical condition
Contraindication to beta-adrenoceptor antagonist or brimonidine therapy

Treatment and study plan

brimonidine/timolol fixed combination

Drug

Primary outcomes

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 1999
Primary completion: 2001
Study completion: 2001
First posted: Jun 1, 2006
Registry last updated: May 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed